Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 2444-2447, 2021.
Article
en Zh
| WPRIM
| ID: wpr-904917
Biblioteca responsable:
WPRO
ABSTRACT
The launch of direct-acting antiviral agents is a milestone in the treatment of hepatitis C, but further studies are needed to explore its specific timing and effectiveness in liver transplantation for HCV-related hepatocellular carcinoma (HCC). This article summarizes related guidelines, consensus statements, and recommendations in China and globally and the advantages of different treatment timing strategies. Furthermore, a retrospective analysis of related studies is performed to investigate the controversial topic of the impact of direct-acting antiviral agents on the recurrence rate of HCV-related HCC after liver transplantation, and it is pointed that direct-acting antiviral agents can reduce the risk of HCC recurrence in liver transplant recipients with HCV-related HCC. The selection of treatment timing should consider various factors such as liver function, waiting time for donors, and utilization of HCV-positive organs.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Guideline
Idioma:
Zh
Revista:
Journal of Clinical Hepatology
Año:
2021
Tipo del documento:
Article